Ugur Sahin
Molecular Biology · 2000–2023
A researcher in the Science corpus: 23 papers; trusts 3 researchers and is trusted by 4 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 158 citations into it; #10,802 of 17,773 by trust here, #1,594 by citations
- Immunology — 116 citations into it
Whom Ugur Sahin trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Ugur Sahin overall
Papers from Ugur Sahin's perspective
Ordered by how strongly the researchers Ugur Sahin trusts endorse each paper. Same corpus, a different order for every researcher.
- Highly efficient reprogramming to pluripotency and directed differentiation of human cells using synthetic modified mRNA (Cell Stem Cell)
- Codon bias and heterologous protein expression. (Trends in Biotechnology)
- Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation (Nucleic Acids Research)
- Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. (Immunity)
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells (Nature Cell Biology)
- Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction (Nature Biotechnology)
- An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 (Cancer Cell)
- A method and server for predicting damaging missense mutations
- Initial sequencing and comparative analysis of the mouse genome (Nature)
- Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft (Nature)
Their papers
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer (2017) — 2,214 citations
- Mutant MHC class II epitopes drive therapeutic immune responses to cancer (2015) — 1,175 citations
- Exploiting the mutanome for tumor vaccination. (2012) — 765 citations
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) — 11,263 citations
- mRNA-based therapeutics — developing a new class of drugs (2014) — 2,098 citations
- Early computational detection of potential high-risk SARS-CoV-2 variants (2021) — 41 citations
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (2020) — 127 citations
- NCOA3 is a selective co-activator of estrogen receptor α-mediated transactivation of PLAC1 in MCF-7 breast cancer cells (2013) — 32 citations
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy (2016) — 1,560 citations
- Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) — 724 citations
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer (2023) — 1,108 citations
- BNT162b vaccines protect rhesus macaques from SARS-CoV-2 (2021) — 629 citations
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) — 1,225 citations
- BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) — 690 citations
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) — 1,578 citations
- An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma (2020) — 861 citations
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) — 2,193 citations
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) — 1,348 citations
- Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020) — 87 citations
- Actively personalized vaccination trial for newly diagnosed glioblastoma (2018) — 806 citations